Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Blood metabolite marker for diagnosing multiple myeloma, and application

A technology for multiple myeloma and metabolites, applied in biological testing, instruments, measuring devices, etc., to achieve accurate and reliable results, simple detection methods, and high sensitivity

Active Publication Date: 2020-02-04
CENT SOUTH UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

No one has used plasma metabolite levels to diagnose MM

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Blood metabolite marker for diagnosing multiple myeloma, and application
  • Blood metabolite marker for diagnosing multiple myeloma, and application
  • Blood metabolite marker for diagnosing multiple myeloma, and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Example 1: Screening Characterization of Differential Metabolites Between Healthy Humans and Multiple Myeloma Patients

[0028] 1. Objects and methods

[0029] 1. The source of the specimen

[0030] After obtaining the consent of the patients, bone marrow samples from 21 HD (healthy donors) and 72 newly diagnosed MM patients, peripheral blood samples from 29 healthy people and 71 newly diagnosed MM patients were collected. All samples were from Xiangya Hospital Affiliated to Central South University , The Third Xiangya Hospital Affiliated to Central South University, Tianjin Hematology Hospital, Chinese Academy of Medical Sciences. All MM patients were diagnosed as MM patients by detecting the type of serum monoclonal immunoglobulin and the proportion of bone marrow plasma cells. All MM patients were newly diagnosed and did not receive treatment to exclude treatment-induced metabolic changes. Both HD and MM patients were from the above three hospitals, and the age, s...

Embodiment 2

[0051] Example 2: Constructing a ROC curve to compare the ability of 5 differential metabolites to diagnose and distinguish MM patients from healthy people

[0052] SPSS23 software was used for ROC curve analysis, and AUC value was calculated, and the ability of 5 differential metabolites in the diagnosis of MM was judged by the abundance levels in bone marrow or peripheral blood. The AUC values ​​of 5 differential metabolites in bone marrow and peripheral blood were: bone marrow stearic acid: AUC=0.90, 95%CI: 0.83-0.95, P<0.0001, bone marrow palmitate: AUC=0.89, 95%CI: 0.81-0.95, P<0.0001, bone marrow aspartate: AUC=0.83, 95%CI: 0.73-0.90, P=0.0095, bone marrow proline: AUC=0.78, 95%CI: 0.65-0.88, P=0.0353 , bone marrow cystine: AUC=0.74, 95%CI: 0.62-0.83, P=0.0188, peripheral blood stearic acid: AUC=0.84, 95%CI: 0.75-0.91, P<0.0001, peripheral blood palmitic acid: AUC=0.82, 95%CI: 0.74-0.90, P<0.0001, peripheral blood aspartate: AUC=0.70, 95%CI: 0.60-0.79, P=0.0213, periphe...

Embodiment 3

[0057] Example 3: Application of 5 Metabolites in Diagnosis of MM

[0058] 1. Objects and methods

[0059] 1. Source of specimen

[0060] After obtaining the consent of the patients, the peripheral venous blood plasma of 25 newly diagnosed patients with HD and 32 patients with MM in the Third Affiliated Hospital of Xiangya Hospital was collected. All MM patients were confirmed by the detection of serum monoclonal immunoglobulin and the proportion of bone marrow plasma cells. HD was age, sex, and body mass index matched to MM patients. The time of blood collection was in the morning on an empty stomach. Plasma samples were stored at -80°C.

[0061] 2. Main reagents

[0062]Acetonitrile, methanol, and formic acid (chromatographic grade) were purchased from Sigma-Aldrich; analytically pure chloroform and pyridine were purchased from China National Pharmaceutical Group Corporation; methoxyamine, N-methyl-N-(trimethylsilane) trifluoroethane Amide (containing 1% trimethylchloro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a blood metabolite marker for diagnosing multiple myeloma, and application. Untargeted metabolomics detection are firstly performed on a healthy donor (HD), and the marrow andperipheral blood sample of a primary-care patient of multiple myeloma (mm) to screen out 5 metabolites that have significant differences in marrows and peripheral blood samples, wherein the 5 metabolites are respectively L_Proline, L_Aspartic acid, L_Cystine, Stearic acid, and Palmitic acid. The analysis result of the ROC curve shows that the 5 different metabolites as a whole can more accuratelydiagnose MM. Targeted metabolomics detection further confirmed that the metabolome composed of these 5 metabolites is an ideal MM diagnostic method. The invention can accurately diagnose MM and is ofgreat significance for promoting the diagnosis of MM in basic research and clinical treatment.

Description

technical field [0001] The invention belongs to the field of biochemistry, and relates to disease diagnosis markers, in particular to blood metabolite markers for diagnosing multiple myeloma, and the application of reagents for detecting blood metabolite markers in preparing preparations for diagnosing multiple myeloma. Background technique [0002] Multiple myeloma (Multiple myeloma, MM) is a malignant plasma cell disease that occurs in the bone marrow cavity. Osteolytic lesions, hypercalcemia, anemia, kidney damage and other clinical symptoms. MM is the second most common hematologic malignancy, accounting for about 15% of all hematologic malignancies in the United States, and 1% of all malignancies, and mostly occurs in the elderly over the age of 70. As China enters an aging society, the incidence of MM has increased in recent years. showing a clear upward trend. MM has no clinical symptoms in the early stage, so that it is mostly in the middle and late stage when it i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N33/68G01N30/02
CPCG01N30/02G01N33/57407G01N33/57488G01N33/6812G01N33/6815
Inventor 周文夏机良张靖宇伍璇武明花向娟娟
Owner CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com